237 related articles for article (PubMed ID: 26839308)
1. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S
Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308
[TBL] [Abstract][Full Text] [Related]
2. Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC.
Wang Y; Liu F; Fang C; Xu L; Chen L; Xu Z; Chen J; Peng W; Fu B; Li Y
Aging (Albany NY); 2021 Jul; 13(14):18223-18237. PubMed ID: 34321364
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
4. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Zhang S; Wu K; Feng J; Wu Z; Deng Q; Guo C; Xia B; Zhang J; Huang H; Zhu L; Zhang K; Shen B; Chen X; Ma S
Oncotarget; 2016 Oct; 7(42):68768-68780. PubMed ID: 27634890
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
8. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
9. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells.
Xie R; Shi J; Cheng C; Yun F; Liu X; Tang P; Wu X; Yang M; Yuan Q
Med Chem; 2016; 12(8):767-774. PubMed ID: 27041553
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
[TBL] [Abstract][Full Text] [Related]
13. Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.
Li R; Huang J; Ma M; Lou Y; Zhang Y; Wu L; Chang DW; Zhao P; Dong Q; Wu X; Han B
Oncotarget; 2016 Oct; 7(42):68360-68370. PubMed ID: 27588392
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
Zhang K; Yang L; Wang J; Sun T; Guo Y; Nelson R; Tong TR; Pangeni R; Salgia R; Raz DJ
Cell Commun Signal; 2019 Dec; 17(1):167. PubMed ID: 31842906
[TBL] [Abstract][Full Text] [Related]
16. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells.
Sun Y; Zheng S; Torossian A; Speirs CK; Schleicher S; Giacalone NJ; Carbone DP; Zhao Z; Lu B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e563-72. PubMed ID: 22197230
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells.
Dong G; Luo J; Kumar V; Dong Z
Am J Physiol Renal Physiol; 2010 Feb; 298(2):F293-300. PubMed ID: 19889954
[TBL] [Abstract][Full Text] [Related]
18. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.
Sears CR; Cooney SA; Chin-Sinex H; Mendonca MS; Turchi JJ
DNA Repair (Amst); 2016 Apr; 40():35-46. PubMed ID: 26991853
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
